Toxicant-Associated Fatty Liver Disease and Liver Neoplastic Progress in Rats Treated with Aflatoxin B1 Alone or in Combination with Extremely Low Frequency EMF

Toxins · 2022 · No effect · Low evidence

← Research stream

No effectLow evidencePaper 821

Low-dose aflatoxin B1 increased steatosis, inflammation, and foci in both sexes, consistent with TAFLD; treated females also showed increases in adenomas and several other liver lesions. The abstract states that 50 Hz ELF-EMF did not produce any enhancing or …

Study snapshot

PublicationToxins · 2022

Study typeanimal

Reported directionNo effect

Evidence ratingLow

Abstract

Toxicant-Associated Fatty Liver Disease and Liver Neoplastic Progress in Rats Treated with Aflatoxin B1 Alone or in Combination with Extremely Low Frequency EMF Vornoli A, Tibaldi E, Gnudi F, Sgargi D, Manservisi F, Belpoggi F, Tovoli F, Mandrioli D. Evaluation of Toxicant- Associated Fatty Liver Disease and Liver Neoplastic Progress in Sprague-Dawley Rats Treated with Low Doses of Aflatoxin B1 Alone or in Combination with Extremely Low Frequency Electromagnetic Fields. Toxins (Basel). 2022 May 3;14(5):325. doi: 10.3390/toxins14050325. PMID: 35622572; PMCID: PMC9143281. Abstract The term toxicant-associated fatty liver disease (TAFLD) has been proposed to describe fatty liver diseases connected to toxicants other than alcohol. Aflatoxins are mycotoxins commonly found as contaminants in foods and feeds, which are known liver toxicants and potential candidates as potential causes of TAFLD. Aflatoxin B1 (AFB1) was administered at low doses to Sprague-Dawley (SD) rats, alone or in combination with S-50 Hz an extremely low frequency electromagnetic field (ELFEMF), to study the evolution of TAFLD, preneoplastic and neoplastic lesions of the liver and the potential enhancing effect of lifespan exposure to ELFEMF. Steatosis, inflammation and foci of different types were significantly increased in both aflatoxin-treated males and females, which is consistent with a pattern of TAFLD. A significant increase in adenomas, cystic dilation of biliary ducts, hepatocellular hyperplasia and hypertrophy and oval cell hyperplasia were also observed in treated females only. The administration of low doses of AFB1 caused TAFLD in SD rats, inducing liver lesions encompassing fatty infiltration, foci of different types and adenomas. Furthermore, the pattern of change observed in preneoplastic liver lesions often included liver steatosis and steatohepatitis (TASH). ELFEMF did not result in any enhancing or toxic effect in the liver of SD rats. Open access paper: ncbi.nlm.nih.gov

Machine Enhanced Logic

AI evidence extraction

Structured fields below were generated from the paper’s abstract and metadata to make the evidence easier to inspect. Automated extraction may be incomplete or incorrect; verify important details against the original paper.

Study typeanimal

Effect directionno_effect

PopulationSprague-Dawley rats (male and female)

Sample sizeNot supplied

ExposureELF · lifespan exposure (stated as 'lifespan exposure to ELFEMF')

Evidence strengthLowConfidence: 74% · Peer reviewed: yes

Main findings

Outcomes measured

toxicant-associated fatty liver disease (TAFLD)
liver steatosis
inflammation
preneoplastic liver lesions (foci)
liver neoplastic lesions (adenomas)
cystic dilation of biliary ducts
hepatocellular hyperplasia and hypertrophy
oval cell hyperplasia
steatohepatitis (TASH)

Limitations

Sample size not reported in the provided abstract/metadata.
ELF-EMF exposure intensity/dose metrics not reported in the provided abstract/metadata.
Details of exposure duration and regimen are not fully specified beyond 'lifespan exposure' in the provided abstract/metadata.

View raw extracted JSON

{
  "study_type": "animal",
  "exposure": {
    "band": "ELF",
    "source": null,
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": "lifespan exposure (stated as 'lifespan exposure to ELFEMF')"
  },
  "population": "Sprague-Dawley rats (male and female)",
  "sample_size": null,
  "outcomes": [
    "toxicant-associated fatty liver disease (TAFLD)",
    "liver steatosis",
    "inflammation",
    "preneoplastic liver lesions (foci)",
    "liver neoplastic lesions (adenomas)",
    "cystic dilation of biliary ducts",
    "hepatocellular hyperplasia and hypertrophy",
    "oval cell hyperplasia",
    "steatohepatitis (TASH)"
  ],
  "main_findings": "Low-dose aflatoxin B1 increased steatosis, inflammation, and foci in both sexes, consistent with TAFLD; treated females also showed increases in adenomas and several other liver lesions. The abstract states that 50 Hz ELF-EMF did not produce any enhancing or toxic effect in the liver of Sprague-Dawley rats when combined with aflatoxin B1.",
  "effect_direction": "no_effect",
  "limitations": [
    "Sample size not reported in the provided abstract/metadata.",
    "ELF-EMF exposure intensity/dose metrics not reported in the provided abstract/metadata.",
    "Details of exposure duration and regimen are not fully specified beyond 'lifespan exposure' in the provided abstract/metadata."
  ],
  "evidence_strength": "low",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "toxicant-associated fatty liver disease",
    "TAFLD",
    "aflatoxin B1",
    "ELF-EMF",
    "extremely low frequency electromagnetic fields",
    "50 Hz",
    "Sprague-Dawley rats",
    "steatosis",
    "steatohepatitis",
    "preneoplastic lesions",
    "adenomas"
  ],
  "suggested_hubs": [
    {
      "slug": "who-icnirp",
      "weight": 0.2,
      "reason": "Involves ELF-EMF exposure and health outcomes; potentially relevant to EMF health risk evaluation context."
    }
  ]
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract and metadata and may be incomplete or incorrect. This material is for informational purposes and is not medical advice.

Identifiers and source

DOI: 10.3390/toxins14050325
PubMed: 35622572

Read the original paper →

Related papers

← Back to the Research Library